​

Intellia Therapeutics Ownership | Who Owns Intellia Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Intellia Therapeutics Ownership Summary

Intellia Therapeutics is owned by 99.51% institutional investors, 4.53% insiders. Ark investment management is the largest institutional shareholder, holding 11.49% of NTLA shares. ARK Disruptive Innovation Full Composite is the top mutual fund, with 8.11% of its assets in Intellia Therapeutics shares.

NTLA Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockIntellia Therapeutics99.51%4.53%-4.04%
SectorHealthcare Stocks 42.53%10.81%46.67%
IndustryBiotech Stocks 45.24%10.75%44.01%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ark investment management11.92M11.49%$205.84B
Vanguard group11.04M10.65%$190.74M
Blackrock9.60M10.05%$214.79M
Blackrock funding, inc. /de9.28M8.94%$160.19M
Morgan stanley6.02M5.81%$104.01M
Contrarius group5.89M5.68%$101.72M
State street4.97M4.79%$85.85M
Goldman sachs group4.28M4.12%$73.89M
Regeneron pharmaceuticals3.70M3.57%$63.95M
Baker bros. advisors lp2.75M2.65%$47.44M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Regeneron pharmaceuticals3.70M9.13%$63.95M
Discovery value fund228.70K7.05%$3.95B
Contrarius group5.89M4.60%$101.72M
Contrarius investment management1.92M2.68%$42.87M
Ark investment management11.92M1.23%$205.84B
Orchard capital management81.60K1.22%$1.41M
Birchview capital, lp60.00K0.78%$1.04M
Generali investments towarzystwo funduszy inwestycyjnych80.00K0.73%$1.38M
Himension capital (singapore) pte.565.13K0.60%$9.76M
Iq eq fund management (ireland)494.47K0.58%$8.54M

Top Buyers

HolderShares% AssetsChange
Contrarius group5.89M4.60%4.34M
Goldman sachs group4.28M0.01%2.23M
Morgan stanley6.02M0.01%1.91M
Jupiter asset management1.36M0.20%1.36M
State street4.97M0.00%931.58K

Top Sellers

HolderShares% AssetsChange
Deep track capital, lp---4.95M
Capital investors---3.78M
Casdin capital---2.00M
Pictet asset management sa---1.39M
Rokos capital management llp---1.14M

New Positions

HolderShares% AssetsChangeValue
Jupiter asset management1.36M0.20%1.36M$23.52M
Farallon capital management607.20K0.04%607.20K$10.49M
Steadfast capital management lp365.40K0.11%365.40K$6.31M
Panagora asset management198.66K0.01%198.66K$3.43M
Point72 asset management174.26K0.01%174.26K$3.01M

Sold Out

HolderChange
Dinuzzo private wealth-1.00
Global financial private client-1.00
Activest wealth management-1.00
Jfs wealth advisors-2.00
Richard w. paul & associates-2.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20252891.05%103,222,25512.82%991.28%143-2.72%76-8.43%
Jun 30, 2025290-7.05%98,735,343-2.49%950.99%146-0.68%85-10.53%
Mar 31, 20256-98.05%3,804,135-96.17%30.04%3-98.41%1-98.55%
Dec 31, 2024286-2.39%92,252,291-1.01%911.07%17817.11%61-27.38%
Sep 30, 2024290-5.54%93,104,8603.35%921.07%150-7.41%84-4.55%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
ARK Disruptive Innovation Full Composite8.71M8.11%966.00
ARK Innovation ETF8.28M7.71%61.21K
American Funds SMALLCAP World A3.78M3.65%3.78M
Vanguard US Total Market Shares ETF3.17M3.06%299.88K
Vanguard Total Stock Mkt Idx Inv3.17M2.95%-70.23K
ARK Genomic Revolution ETF2.89M2.69%-10.31K
ARK Genomic Revolution2.88M2.68%-220.20K
Vanguard Small Cap Index2.51M2.34%-16.78K
iShares Russell 2000 ETF2.48M2.31%-
Nikko AM ARK Disruptive Innovation A USD1.76M1.70%-68.46K

Recent Insider Transactions

DateNameRoleActivityValue
Oct 01, 2025Schultes Birgit C EVP, Chief Scientific OfficerSell$538.78
Oct 01, 2025Dube Michael P VP, Chief Accounting OfficerSell$32.52K
Aug 20, 2025CHASE WILLIAM J-Buy$1.00M
Jul 23, 2025Dulac Edward J III EVP, Chief Financial OfficerSell$104.62K
Jul 01, 2025Clark Eliana EVP, Chief Technical OfficerSell$10.04K

Insider Transactions Trends

DateBuySell
2025 Q4-2
2025 Q314
2025 Q2-2
2025 Q1-11
2024 Q4-1

NTLA Ownership FAQ

Who Owns Intellia Therapeutics?

Intellia Therapeutics shareholders are primarily institutional investors at 99.51%, followed by 4.53% insiders and -4.04% retail investors. The average institutional ownership in Intellia Therapeutics's industry, Biotech Stocks , is 45.24%, which Intellia Therapeutics exceeds.

Who owns the most shares of Intellia Therapeutics?

Intellia Therapeutics’s largest shareholders are Ark investment management (11.92M shares, 11.49%), Vanguard group (11.04M shares, 10.65%), and Blackrock (9.6M shares, 10.05%). Together, they hold 32.19% of Intellia Therapeutics’s total shares outstanding.

Does Blackrock own Intellia Therapeutics?

Yes, BlackRock owns 10.05% of Intellia Therapeutics, totaling 9.6M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 214.79M$. In the last quarter, BlackRock increased its holdings by 488.34K shares, a 5.36% change.

Who is Intellia Therapeutics’s biggest shareholder by percentage of total assets invested?

Regeneron pharmaceuticals is Intellia Therapeutics’s biggest shareholder by percentage of total assets invested, with 9.13% of its assets in 3.7M Intellia Therapeutics shares, valued at 63.95M$.

Who is the top mutual fund holder of Intellia Therapeutics shares?

ARK Disruptive Innovation Full Composite is the top mutual fund holder of Intellia Therapeutics shares, with 8.11% of its total shares outstanding invested in 8.71M Intellia Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools